S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:SRDX

Surmodics - SRDX Stock Forecast, Price & News

$21.79
+2.56 (+13.31%)
(As of 03/28/2023 04:00 PM ET)
Add
Compare
Today's Range
$19.01
$22.13
50-Day Range
$17.13
$37.34
52-Week Range
$16.00
$45.85
Volume
342,283 shs
Average Volume
188,345 shs
Market Capitalization
$307.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00

Surmodics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
117.3% Upside
$47.00 Price Target
Short Interest
Healthy
4.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.52
Upright™ Environmental Score
News Sentiment
0.36mentions of Surmodics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.93) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

516th out of 1,002 stocks

Surgical & Medical Instruments Industry

56th out of 104 stocks


SRDX stock logo

About Surmodics (NASDAQ:SRDX) Stock

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Stock News Headlines

A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
JP Morgan analyst: Oil to hit $380 per barrel
JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.
Needham Reaffirms Their Buy Rating on SurModics (SRDX)
SurModics (SRDX) Reports Q1 Loss, Tops Revenue Estimates
Earnings Outlook For Surmodics
Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates
See More Headlines
Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

SRDX Company Calendar

Last Earnings
2/06/2023
Today
3/28/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:SRDX
CUSIP
86887310
Employees
389
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+144.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-27,270,000.00
Pretax Margin
-26.49%

Debt

Sales & Book Value

Annual Sales
$99.95 million
Book Value
$7.75 per share

Miscellaneous

Free Float
13,066,000
Market Cap
$271.72 million
Optionable
Optionable
Beta
0.96

Social Links


Key Executives

  • Gary R. MaharajGary R. Maharaj
    President, Chief Executive Officer & Director
  • Timothy J. Arens
    CFO, SVP-Finance & Information Technology
  • Charles W. OlsonCharles W. Olson
    President-Medical Device Coatings & SVP
  • Teri L. W. Sides
    President-Vascular Interventions & SVP
  • John D. Manders
    Vice President-Finance & Controller













SRDX Stock - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings
or view top-rated stocks.

What is Surmodics' stock price forecast for 2023?

2 equities research analysts have issued twelve-month target prices for Surmodics' shares. Their SRDX share price forecasts range from $34.00 to $60.00. On average, they predict the company's stock price to reach $47.00 in the next twelve months. This suggests a possible upside of 144.4% from the stock's current price.
View analysts price targets for SRDX
or view top-rated stocks among Wall Street analysts.

How have SRDX shares performed in 2023?

Surmodics' stock was trading at $34.12 on January 1st, 2023. Since then, SRDX shares have decreased by 43.6% and is now trading at $19.23.
View the best growth stocks for 2023 here
.

Are investors shorting Surmodics?

Surmodics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 544,500 shares, an increase of 24.8% from the February 28th total of 436,400 shares. Based on an average trading volume of 169,200 shares, the short-interest ratio is presently 3.2 days. Approximately 4.0% of the shares of the company are short sold.
View Surmodics' Short Interest
.

When is Surmodics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our SRDX earnings forecast
.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) released its quarterly earnings results on Monday, February, 6th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.13. The company earned $24.93 million during the quarter, compared to the consensus estimate of $24.19 million. Surmodics had a negative trailing twelve-month return on equity of 15.61% and a negative net margin of 31.71%. During the same quarter in the previous year, the business posted ($0.13) EPS.

What ETFs hold Surmodics' stock?
What guidance has Surmodics issued on next quarter's earnings?

Surmodics updated its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share (EPS) guidance of -$2.09--$1.69 for the period, compared to the consensus EPS estimate of -$2.38. The company issued revenue guidance of $102.00 million-$106.00 million, compared to the consensus revenue estimate of $104.84 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

Who are Surmodics' major shareholders?

Surmodics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Soleus Capital Management L.P. (5.49%), Renaissance Technologies LLC (4.11%), Dimensional Fund Advisors LP (3.14%), Millennium Management LLC (1.98%), Geode Capital Management LLC (1.78%) and Charles Schwab Investment Management Inc. (0.74%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends
.

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surmodics' stock price today?

One share of SRDX stock can currently be purchased for approximately $19.23.

How much money does Surmodics make?

Surmodics (NASDAQ:SRDX) has a market capitalization of $271.72 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

How many employees does Surmodics have?

The company employs 389 workers across the globe.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001.

This page (NASDAQ:SRDX) was last updated on 3/28/2023 by MarketBeat.com Staff